| scholarly article | Q13442814 |
| P50 | author | Joseph Schlessinger | Q2908140 |
| P2093 | author name string | Matthew J Davis | |
| P2860 | cites work | The protein kinase complement of the human genome | Q24324497 |
| The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling | Q24337017 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus | Q24595462 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| A census of human cancer genes | Q24647081 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Characterization of murine A-raf, a new oncogene related to the v-raf oncogene | Q28592226 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design | Q31145317 | ||
| MAP kinase pathways | Q33650641 | ||
| Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy | Q35920288 | ||
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| B-raf, a new member of the raf family, is activated by DNA rearrangement | Q40650163 | ||
| Molecular cloning of the avian acute transforming retrovirus MH2 reveals a novel cell-derived sequence (v-mil) in addition to the myc oncogene | Q41466238 | ||
| BRAFMutation in Metastatic Colorectal Cancer | Q61481269 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15-19 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Journal of Cell Biology | Q1524550 |
| P1476 | title | The genesis of Zelboraf: targeting mutant B-Raf in melanoma | |
| P478 | volume | 199 |
| Q41906937 | Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position. |
| Q42545907 | Cell biology: at the center of modern biomedicine |
| Q42095882 | Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth |
| Q35033532 | Extracellular metabolic energetics can promote cancer progression |
Search more.